DXCM logo

DEXCOM INC

DXCMNASDAQ
πŸ† #397 by market capEarnings Feb 10 Β· PostUS Equity
$79.32β–Ό $0.87 (βˆ’1.08%)
Market closed Β· at close
πŸ””
Track DXCM
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.1%
7dβ–Ό 4.8%
14dβ–Ό 0.1%
30dβ–² 1.8%
ytdβ–² 19.5%
1yβ–² 31.7%
🏦Market Cap
$29.58B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
13.0%
Healthy
πŸ“ŠGross Margin
65.2%
High
πŸ’΅FCF Margin
21.5%
Strong
βš–οΈP/S Ratio
5.9x
Fair
Otter Score
76
Strong

Trading Snapshot

Day Range
$78.75 – $81.58
52-Week Range
$56.72 – $92.59
Volume (shares)
4,608,314
Avg Volume (shares)
β€”
Shares Outstanding
372.9M
Next Earnings
2027-02-10

Fundamentals Snapshot

Annual Revenue
$4.66B
Last Q Revenue
$1.34B
P/E Ratio
30.2
P/S Ratio
5.9x
EPS (TTM)
$2.53
Dividend Yield
β€”
Dilution (1yr)
βˆ’1.9%
DXCM logo

DEXCOM INC

DXCM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4.7Bβ–² +15.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
60.1%β–Ό βˆ’0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$912Mβ–² +52.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.1Bβ–² +70.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
398.9Mβ–Ό βˆ’1.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$472Mβ–² +$1.5B YoY
StockOtter Β· stockotter.space

About DEXCOM INC

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

News unavailable.